Cancer

Second Quarter Report 2007

Published in Cancer Weekly, September 11th, 2007

Clavis Pharma ASA continued its research and development focus during the second quarter 2007, with three cancer drug candidates in development.

Clavis Pharma has initiated a Phase II combination study of ELACYT(TM) and Nexavar(TM) (sorafenib) in previously treated malignant melanoma patients. This is an important development, and the first clinical trial where ELACYT is used in combination with another cancer drug. In the second quarter, the ELACYT Clinical Phase II study in metastatic colorectal cancer has progressed according to plan, with patient recruitment ongoing at three centres in the UK.

The work with ELACYT in blood cancers has been...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry